Urinary clusterin as a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan: An exploratory analysis from the SONAR trial

W Wenjun Ju V Viji Nair P Priya Vart J J. David Smeijer (Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands) K Kelly L. Hudkins E Erik Moedt M Maria Larkina P Paul Perco F Frederic Burdet K Kerby Shedden M Michael Hwang E Edmond Lee C Christopher O’Connor J John Hartman L Lalita Subramanian M Markus Bitzer M Mark Ibberson K Kevin L. Duffin M Maria F. Gomez C Charles E. Alpers M Matthias Kretzler H Hiddo J. L. Heerspink